Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly (NYSE:LLY) has filed for a six-part note offering, with the aggregate principal amount of the notes offered ...

BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect.

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...